Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Autoimmune bullous diseases - ocular manifestations and management|
|Citation:||Drugs, 2005; 65(13):1767-1779|
|Publisher:||Adis International Ltd|
|Abstract:||The ocular manifestations of autoimmune bullous diseases are common and potentially sight-threatening. Major ophthalmic involvement is most commonly seen in mucous membrane pemphigoid (cicatricial pemphigoid), epidermolysis bullosa acquisita, linear IgA bullous disease, pemphigus vulgaris and paraneoplastic pemphigus. The main pathological process is related to autoimmune-induced conjunctival inflammation with consequent lid and corneal pathology, which may eventually result in permanent visual loss. Ocular involvement can be asymptomatic. Early detection is aided by careful attention to symptoms and signs of early ophthalmic disease. Ocular disease can be difficult to treat and management usually involves systemic therapy with immunomodulators to control inflammation and prevent progression to irreversible blindness, as well as surgical intervention in advanced disease. Recent advances in treatment, including methotrexate, mycophenolate mofetil, monoclonal antibodies and topical tacrolimus therapies, have led to promising results.|
|Keywords:||Humans; Eye Diseases; Skin Diseases, Vascular; Autoimmune Diseases; Anti-Inflammatory Agents; Immunologic Factors; Administration, Topical|
|Appears in Collections:||Surgery publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.